Reviewing CochLear (OTCMKTS:CHEOY) and Medpace (NASDAQ:MEDP)

CochLear (OTCMKTS:CHEOY) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares CochLear and Medpace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CochLear	N/A	N/A	N/A
Medpace	17.83%	118.82%	25.07%

Analyst Recommendations

This is a summary of recent ratings and price targets for CochLear and Medpace, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CochLear	0	2	1	2	3.00
Medpace	1	9	5	0	2.27

Medpace has a consensus price target of $486.67, indicating a potential downside of 2.34%. Given Medpace’s higher possible upside, analysts plainly believe Medpace is more favorable than CochLear.

Valuation & Earnings

This table compares CochLear and Medpace”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CochLear	$1.53 billion	5.20	$251.85 million	N/A	N/A
Medpace	$2.53 billion	5.63	$451.12 million	$15.30	32.57

Medpace has higher revenue and earnings than CochLear.

Insider and Institutional Ownership

78.0% of Medpace shares are held by institutional investors. 20.3% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

CochLear has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.

Summary

Medpace beats CochLear on 11 of the 13 factors compared between the two stocks.

About CochLear

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.